Sibenadet HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 327000

CAS#: 154189-24-9 (HCl)

Description: Sibenadet, also known as AR-C-68397AA; FPL-68397; ARC-68397AA, is a D2/beta2-agonist and is potential useful for the treatment of symptoms of chronic obstructive pulmonary disease. (last updated: 10/13/2016)

Chemical Structure

img
Sibenadet HCl
CAS# 154189-24-9 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 327000
Name: Sibenadet HCl
CAS#: 154189-24-9 (HCl)
Chemical Formula: C22H29ClN2O5S2
Exact Mass: 0.00
Molecular Weight: 501.053
Elemental Analysis: C, 52.74; H, 5.83; Cl, 7.08; N, 5.59; O, 15.97; S, 12.80

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 154189-40-9 (free base)   154189-24-9 (HCl)    

Synonym: Sibenadet Hydrochloride; AR-C-68397AA; FPL-68397; ARC-68397AA; Viozan.

IUPAC/Chemical Name: 4-Hydroxy-7-(2-(2-(3-phenylethoxy-propane-1-sulfonyl)-ethylamino)ethyl)-3H-benzothiazol-2-one hydrochloride.

InChi Key: YXOKBHUPEBNZOG-UHFFFAOYSA-N

InChi Code: InChI=1S/C22H28N2O5S2.ClH/c25-19-8-7-18(21-20(19)24-22(26)30-21)9-11-23-12-16-31(27,28)15-4-13-29-14-10-17-5-2-1-3-6-17;/h1-3,5-8,23,25H,4,9-16H2,(H,24,26);1H

SMILES Code: O=C1SC2=C(CCNCCS(=O)(CCCOCCC3=CC=CC=C3)=O)C=CC(O)=C2N1.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# 154189-40-9 (Sibenadet) 154189-24-9 (Sibenadet Hydrochloride)

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 501.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bradley JP, Pickard CJ, Burley JC, Martin DR, Hughes LP, Cosgrove SD, Brown SP. Probing intermolecular hydrogen bonding in sibenadet hydrochloride polymorphs by high-resolution (1) H double-quantum solid-state NMR spectroscopy. J Pharm Sci. 2012 May;101(5):1821-30. doi: 10.1002/jps.23078. Epub 2012 Feb 22. PubMed PMID: 22359321.

2: Alcaraz L, Bailey A, Cadogan E, Connolly S, Jewell R, Jordan S, Kindon N, Lister A, Lawson M, Mullen A, Dainty I, Nicholls D, Paine S, Pairaudeau G, Stocks MJ, Thorne P, Young A. From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists. Bioorg Med Chem Lett. 2012 Jan 1;22(1):689-95. doi: 10.1016/j.bmcl.2011.10.049. Epub 2011 Oct 20. PubMed PMID: 22079756.

3: Connolly S, Alcaraz L, Bailey A, Cadogan E, Christie J, Cook AR, Fisher AJ, Hill S, Humphries A, Ingall AH, Kane Z, Paine S, Pairaudeau G, Stocks MJ, Young A. Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists. Bioorg Med Chem Lett. 2011 Aug 1;21(15):4612-6. doi: 10.1016/j.bmcl.2011.05.097. Epub 2011 Jun 13. PubMed PMID: 21723724.

4: Newbold P, Sanders N, Reele SB. Lack of correlation between exercise and sibenadet-induced changes in heart rate corrected measurement of the QT interval. Br J Clin Pharmacol. 2007 Mar;63(3):279-87. Epub 2006 Sep 12. PubMed PMID: 17380588; PubMed Central PMCID: PMC2000729.

5: Cosgrove SD, Steele G, Austin TK, Plumb AP, Stensland B, Ferrari E, Roberts KJ. Understanding the polymorphic behavior of sibenadet hydrochloride through detailed studies integrating structural and dynamical assessment. J Pharm Sci. 2005 Nov;94(11):2403-15. PubMed PMID: 16200581.

6: Hasani A, Toms N, Agnew JE, Lloyd J, Dilworth JP. Mucociliary clearance in COPD can be increased by both a D2/beta2 and a standard beta2 agonists. Respir Med. 2005 Feb;99(2):145-51. PubMed PMID: 15715181.

7: Fozard JR, Buescher H, Farr DC, Mazzoni L. Suppression of histamine-induced tachypnoea in the rhesus monkey by sibenadet: no role for dopamine D2 receptors. Auton Autacoid Pharmacol. 2004 Jan;24(1):9-16. PubMed PMID: 15307823.

8: Källén A. Multivariate estimation of the relative dose potency. Stat Med. 2004 Jul 30;23(14):2187-93. PubMed PMID: 15236424.

9: Calverley P, Keating ET, Goldman M, Casty F. Conclusion. Lessons from the novel D2 dopamine receptor, beta2-adrenoceptor agonist, Viozan: chronic obstructive pulmonary disease and drug development implications. Respir Med. 2003 Jan;97 Suppl A:S71-4. PubMed PMID: 12564613.

10: Leidy NK, Schmier JK, Jones MK, Lloyd J, Rocchiccioli K. Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough and Sputum Scale. Respir Med. 2003 Jan;97 Suppl A:S59-70. PubMed PMID: 12564612.

11: O'Brien JA, Ward AJ, Jones MK, McMillan C, Lordan N. Utilization of health care services by patients with chronic obstructive pulmonary disease. Respir Med. 2003 Jan;97 Suppl A:S53-8. PubMed PMID: 12564611.

12: Hiller FC, Alderfer V, Goldman M. Long-term use of Viozan (sibenadet HCl) in patients with chronic obstructive pulmonary disease: results of a 1-year study. Respir Med. 2003 Jan;97 Suppl A:S45-52. PubMed PMID: 12564610.

13: Celli B, Halpin D, Hepburn R, Byrne N, Keating ET, Goldman M. Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS). Respir Med. 2003 Jan;97 Suppl A:S35-43. PubMed PMID: 12564609.

14: Laursen LC, Lindqvist A, Hepburn T, Lloyd J, Perrett J, Sanders N, Rocchiccioli K. The role of the novel D2/beta2-agonist, Viozan (sibenadet HCl), in the treatment of symptoms of chronic obstructive pulmonary disease: results of a large-scale clinical investigation. Respir Med. 2003 Jan;97 Suppl A:S23-33. PubMed PMID: 12564608.

15: Ind PW, Laitinen L, Laursen L, Wenzel S, Wouters E, Deamer L, Nystrom P. Early clinical investigation of Viozan (sibenadet HCl), a novel D2 dopamine receptor, beta2-adrenoceptor agonist for the treatment of chronic obstructive pulmonary disease symptoms. Respir Med. 2003 Jan;97 Suppl A:S9-21. PubMed PMID: 12564607.

16: Dougall IG, Young A, Ince F, Jackson DM. Dual dopamine D2 receptor and beta2-adrenoceptor agonists for the treatment of chronic obstructive pulmonary disease: the pre-clinical rationale. Respir Med. 2003 Jan;97 Suppl A:S3-7. PubMed PMID: 12564606.

17: Rennard SI. Introduction. The symposium that never occurred: pre-clinical and clinical development of sibenadet. Respir Med. 2003 Jan;97 Suppl A:S1-2. PubMed PMID: 12564605.

18: Lindsey JK, Stevens JW, Jones B, Jackson D. Dynamic modelling of a challenge-escalation cross-over study of treatment of capsaicin-induced coughing. Stat Med. 2002 Oct 30;21(20):3023-33. PubMed PMID: 12369079.

19: Fozard JR, Baur F, Wolber C, Collingwood SP. Inhibition by viozan of extravasation induced in rat trachea by capsaicin is mediated exclusively by beta 2-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):570-2. PubMed PMID: 11770013.

20: Willson VJ, Lockley WJ, Mather A, Singh J, Gilbert CM, Bayliss MA, Wilkinson D. A time-resolved fluorescence immunoassay for the determination of a novel respiratory therapeutic agent, AR-C68397XX (Viozan) in human plasma. J Pharm Biomed Anal. 2000 Nov;23(6):947-54. PubMed PMID: 11095295.